Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 23

Cited In for PubMed (Select 18457324)

1.

Patient-Specific Pluripotent Stem Cells in Doxorubicin Cardiotoxicity: A New Window Into Personalized Medicine.

Bernstein D, Burridge P.

Prog Pediatr Cardiol. 2014 Dec 1;37(1-2):23-27. No abstract available.

PMID:
25530693
2.

The emerging era of pharmacogenomics: current successes, future potential, and challenges.

Lee JW, Aminkeng F, Bhavsar AP, Shaw K, Carleton BC, Hayden MR, Ross CJ.

Clin Genet. 2014 Jul;86(1):21-8. doi: 10.1111/cge.12392. Epub 2014 May 9. Review.

3.

The role of iron in anthracycline cardiotoxicity.

Gammella E, Maccarinelli F, Buratti P, Recalcati S, Cairo G.

Front Pharmacol. 2014 Feb 26;5:25. doi: 10.3389/fphar.2014.00025. eCollection 2014. Review.

4.

Interindividual variability in the cardiac expression of anthracycline reductases in donors with and without Down syndrome.

QuiƱones-LombraƱa A, Ferguson D, Hageman Blair R, Kalabus JL, Redzematovic A, Blanco JG.

Pharm Res. 2014 Jul;31(7):1644-55. doi: 10.1007/s11095-013-1267-1. Epub 2014 Feb 22.

PMID:
24562808
5.

A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor.

Lubieniecka JM, Graham J, Heffner D, Mottus R, Reid R, Hogge D, Grigliatti TA, Riggs WK.

Front Genet. 2013 Nov 11;4:231. doi: 10.3389/fgene.2013.00231. eCollection 2013.

6.

Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation.

Armenian SH, Ding Y, Mills G, Sun C, Venkataraman K, Wong FL, Neuhausen SL, Senitzer D, Wang S, Forman SJ, Bhatia S.

Br J Haematol. 2013 Oct;163(2):205-13. doi: 10.1111/bjh.12516. Epub 2013 Aug 8.

7.

Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity.

Jensen BC, McLeod HL.

Pharmacogenomics. 2013 Jan;14(2):205-13. doi: 10.2217/pgs.12.205. Review.

8.

Children's Oncology Group's 2013 blueprint for research: survivorship and outcomes.

Armenian SH, Landier W, Hudson MM, Robison LL, Bhatia S; COG Survivorship and Outcomes Committee.

Pediatr Blood Cancer. 2013 Jun;60(6):1063-8. doi: 10.1002/pbc.24422. Epub 2012 Dec 19. Review.

9.

Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.

Khouri MG, Douglas PS, Mackey JR, Martin M, Scott JM, Scherrer-Crosbie M, Jones LW.

Circulation. 2012 Dec 4;126(23):2749-63. doi: 10.1161/CIRCULATIONAHA.112.100560. Review. No abstract available.

10.

DNA sequence variants in the carbonyl reductase 1 (cbr1) gene in seven breeds of Canis lupus familiaris.

Cheng Q, Sanborn C, Ferguson D, Blanco JG.

Genet Mol Res. 2012 Apr 27;11(2):1109-16. doi: 10.4238/2012.April.27.10.

11.

Dietary inorganic nitrate alleviates doxorubicin cardiotoxicity: mechanisms and implications.

Xi L, Zhu SG, Das A, Chen Q, Durrant D, Hobbs DC, Lesnefsky EJ, Kukreja RC.

Nitric Oxide. 2012 May 15;26(4):274-84. doi: 10.1016/j.niox.2012.03.006. Epub 2012 Apr 5. Review.

12.

Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.

Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W, Mays A, Friedman DL, Ginsberg JP, Hudson MM, Neglia JP, Oeffinger KC, Ritchey AK, Villaluna D, Relling MV, Bhatia S.

J Clin Oncol. 2012 May 1;30(13):1415-21. doi: 10.1200/JCO.2011.34.8987. Epub 2011 Nov 28.

13.

A conserved antioxidant response element (ARE) in the promoter of human carbonyl reductase 3 (CBR3) mediates induction by the master redox switch Nrf2.

Cheng Q, Kalabus JL, Zhang J, Blanco JG.

Biochem Pharmacol. 2012 Jan 1;83(1):139-48. doi: 10.1016/j.bcp.2011.09.027. Epub 2011 Oct 5.

14.

Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors.

Bhatia S.

Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2048-67. doi: 10.1158/1055-9965.EPI-11-0659. Review.

15.

National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage and dysfunction.

Nieder ML, McDonald GB, Kida A, Hingorani S, Armenian SH, Cooke KR, Pulsipher MA, Baker KS.

Biol Blood Marrow Transplant. 2011 Nov;17(11):1573-84. doi: 10.1016/j.bbmt.2011.09.013. Epub 2011 Oct 1.

16.

Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health.

Ness KK, Armenian SH, Kadan-Lottick N, Gurney JG.

Expert Rev Hematol. 2011 Apr;4(2):185-97. doi: 10.1586/ehm.11.8. Review.

17.

Cardiovascular effects in childhood cancer survivors treated with anthracyclines.

Franco VI, Henkel JM, Miller TL, Lipshultz SE.

Cardiol Res Pract. 2011 Feb 10;2011:134679. doi: 10.4061/2011/134679.

18.

Doxorubicin pathways: pharmacodynamics and adverse effects.

Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB.

Pharmacogenet Genomics. 2011 Jul;21(7):440-6. doi: 10.1097/FPC.0b013e32833ffb56. No abstract available.

19.

Chronic health conditions in childhood cancer survivors: is it all treatment-related--or do genetics play a role?

Armenian SH, Bhatia S.

J Gen Intern Med. 2009 Nov;24 Suppl 2:S395-400. doi: 10.1007/s11606-009-0995-8. Review.

20.

Long-term consequences of hematopoietic stem cell transplantation: current state of the science.

Baker KS, Armenian S, Bhatia S.

Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S90-6. doi: 10.1016/j.bbmt.2009.09.017. Epub 2009 Sep 24. Review. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk